ClinicalTrials.gg
RecruitingNCT07704918Updated Nov 2, 2026

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

An interventional study of Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran) in Melanoma, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 2, 2026Eligibility revisedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,050 studies in Melanoma with a site in United States — 242 open to participants now, 437 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
825th of 1,750
40 · median 37
Started
2026
with 50 others
No phase
159 of 2,050
31 open now
Primary completion
2027-12
later than 260 of 432 live
Registered
2,034th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 825th largest by planned enrollment of the 1,750 interventional ones that give a count, is one of 51 that started in 2026, is one of 159 with no phase, reaches primary completion later than 260 of the 432 other live ones, and was the 2,034th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

242 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

236 more — sign in →

All 242 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

Immune checkpoint inhibitors (ICIs) are a class of medications that are now standard in the treatment of melanoma. These are standard therapy for melanoma, but long-term side effects on disease in the heart arteries is poorly understood. In this study, melanoma patients receiving ICIs for the first time will undergo a coronary computed tomography angiography (CCTA) scan. CCTA results will be analyzed by the FDA-approved Cleerly TM image analysis pipeline. Patients with disease in their heart arteries will be randomized to usual care or aggressive lipid lowering therapy. Those in the aggressive lipid lowering therapy arm will be seen by a cardiologist and placed on standard lipid lowering medications with a goal of achieving an LDL-C ≤ 55mg/dL. Follow-up CCTA scans will occur at 12-month and 24-month timepoints. The primary outcome of interest will be differences in LDL-C levels between the two arms at the 12-month timepoint. The secondary outcome of interest will be the differences in total plaque volume between the two arms at the 12-month timepoint.

03

Conditions studied

  • Melanoma

Keywords

  • atherosclerosis
  • coronary artery disease
  • coronary atherosclerosis
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision to sign and date the consent form.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.
  • Be a male aged ≥55 years or a female aged ≥65 years.
  • For those able to bear children, documentation or report of menopausal status via approximate last menstrual period or hysterectomy due to of pregnancy for the CCTA procedure. Those without documentation or report of menopausal status require a negative urine pregnancy test (serum pregnancy test will only be done if needed to confirm an ambiguous or positive urine test).
  • 5. Have a melanoma diagnosis without prior course(s) of ICI use and planning to start (or currently on) first course of ICI therapy (, PD-L1, CTLA-4, LAG3). ICI start can occur prior to consent (up to 90 days prior to eligibility CCTA) as long as it is first exposure. ICI therapy can be received as standard of care or other trial treatment for their cancer.
  • Plaque stage ≥ 1 on screening CCTA.

Exclusion criteria

Exclusion Criteria:

  • Any prior major cardiovascular event, defined as myocardial infarction, stroke, coronary revascularization, or other major cardiovascular event determined to be significant by the principal investigator.
  • Meeting any of the standard CCTA listed below:
  • Allergy to iodinated contrast or history of contrast-induced nephropathy
  • Renal insufficiency ( \< 45 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation). A current eGFR value (collected/calculated within 3 months prior to signing the consent form or at screening) is required at baseline.
  • Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute). must be performed within 1 year prior to signing the consent form or at screening.
  • Hemodynamic instability
  • Weight > 400 lbs. (181 kg) or above manufacturer-recommended limit for scanner and table, whichever is lower
  • Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment
  • Pregnancy
  • Inability to hold breath for > 10 seconds
  • Contraindication to dosing with beta blocker as needed or nitroglycerin prior to CCTA procedure
  • Inability to cooperate with scan acquisition and/or breath-hold instructions
  • Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA
  • If a patient's fast LDL-C is > 190 mg/dL, this is consistent with underlying familial hypercholesterolemia, and they will not be eligible for the study. A current value must be collected within 90 days prior to signing the consent form or at screening.
  • If a patient's CCTA demonstrates previously undiagnosed obstructive coronary disease, they will not be eligible for the study. Obstructive disease will be defined as >50% obstruction in the left main coronary artery, or >70% obstruction elsewhere in the coronary tree.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Active Comparator: Usual Care

    Active Comparator: Usual Care: 12- and 24-month follow-up CCTA with plaque staging, lipid panel

  • Experimental
    Aggressive Lipid Lowering Therapy

    Participants in the 'aggressive lipid lowering therapy' arm will receive guideline-directed lipid lowering therapy (statins and/or PCSK9 inhibitors) managed by a cardiologist. Dosing adjustments will be guided by individual patient response and standard-of-care practices, with the goal of achieving LDL-C ≤55 mg/dL.

    Drug: Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)

Interventions

  • DrugStatins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)

    Drug pages: StatinsStudies of StatinsStatins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EzetimibeStudies of EzetimibeEzetimibe pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PCSK9 InhibitorStudies of PCSK9 InhibitorPCSK9 Inhibitor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to the aggressive lipid lowering therapy arm will receive Guideline-directed lipid-lowering therapy (statins and/or ezetimibe and/or PCSK9 inhibitors) managed by a cardiologist with dose adjustments to achieve LDL-C ≤55 mg/dL.

06

What researchers measure

Primary outcomes

  1. Mean change in LDL-C from baseline to 12 months

    Each participant will have LDL-C measured prior to randomization and at the 12-month timepoint. The mean change in LDL-C (mg/dL) from baseline to 12 months will be calculated for each participant. The mean change will be compared between the aggressive lipid-lowering therapy arm and the usual care arm.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. Change in Total Plaque Volume from Baseline to 12 months

    Each participant will have total plaque volume measured prior to randomization and at the 12-month timepoint via Cleerly TM's CCTA image analysis pipeline. The mean change in total coronary plaque volume (mm³), as measured by coronary computed tomography angiography (CCTA) using the Cleerly™ image analysis pipeline, from baseline to 12 months will be calculated for each participant and compared between study arms.

    Time frame: 12 months

  2. Major adverse cardiovascular events at 12 months

    Major adverse cardiovascular events between 0 and 12 months will be noted to determine if there is a difference in major adverse cardiovascular events (MACE) rates between the usual care arm versus the aggressive lipid lowering arm.

    Time frame: 12 months

  3. Change in the Proportion of Calcified Plaque Volume from Baseline to 12 Months

    Each participant will have proportion of calcified plaque volume measured prior to randomization and at the 12-month timepoint via Cleerly TM's CCTA image analysis pipeline. The difference between these two timepoints in each participant will be calculated to determine if there is a significant difference between proportion of calcified plaque volume changes in the usual care arm versus the aggressive lipid lowering arm.

    Time frame: 12 months

  4. Change in Size of the Largest Plaque from Baseline to 12 Months

    Each participant will have the size of the largest plaque (by volume) measured prior to randomization and at the 12-month timepoint via Cleerly TM's CCTA image analysis pipeline. The difference between these two timepoints in each participant will be calculated to determine if there is a significant difference between largest plaque volume changes in the usual care arm versus the aggressive lipid lowering arm.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 14 months is below that.

Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.

Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 15, 2026
StartActual
Oct 19, 2026was Dec 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 31, 2026→Oct 19, 2026 (actual)
Oct 22, 2026
Eligibility
2 inclusion criteria edited; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedFor those able to bear children, documentation or report of menopausal status via approximate last menstrual period or hysterectomy due to contraindication of pregnancy for the CCTA procedure. Those without documentation or report of menopausal status require a negative urine pregnancy test (serum pregnancy test will only be done if needed to confirm an ambiguous or positive urine test).
  • Edited5. Have a melanoma diagnosis without prior course(s) of ICI use and planning to start (or currently on) first course of ICI therapy (PD-1, PD-L1, CTLA-4, LAG3). ICI start can occur prior to consent (up to 90 days prior to eligibility CCTA) as long as it is first exposure. ICI therapy can be received as standard of care or other trial treatment for their cancer.
Exclusion criteria
  • EditedRenal insufficiency (eGFR < 45 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation). A current eGFR value (collected/calculated within 3 months fromprior to signing the consent form or at screening visit) is required at baseline.
  • EditedActive arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute). EKG must be performed within 1 year ofprior to signing the consent form or at screening visit.
  • EditedIf a patient's fast LDL-C is > 190 mg/dL, this is consistent with underlying familial hypercholesterolemia, and they will not be eligible for the study. A current value must be collected within 90 days prior to signing the consent form or at screening.
Nov 2, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange in the Proportion of Calcified Plaque Volume from Baseline to 12 MonthsTime frame: 12 months
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Eligibility 2 inclusion criteria edited; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedFor those able to bear children, documentation or report of menopausal status via approximate last menstrual period or hysterectomy due to contraindication of pregnancy for the CCTA procedure. Those without documentation or report of menopausal status require a negative urine pregnancy test (serum pregnancy test will only be done if needed to confirm an ambiguous or positive urine test).
    • Edited5. Have a melanoma diagnosis without prior course(s) of ICI use and planning to start (or currently on) first course of ICI therapy (PD-1, PD-L1, CTLA-4, LAG3). ICI start can occur prior to consent (up to 90 days prior to eligibility CCTA) as long as it is first exposure. ICI therapy can be received as standard of care or other trial treatment for their cancer.
    Exclusion criteria
    • EditedRenal insufficiency (eGFR < 45 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation). A current eGFR value (collected/calculated within 3 months fromprior to signing the consent form or at screening visit) is required at baseline.
    • EditedActive arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute). EKG must be performed within 1 year ofprior to signing the consent form or at screening visit.
    • EditedIf a patient's fast LDL-C is > 190 mg/dL, this is consistent with underlying familial hypercholesterolemia, and they will not be eligible for the study. A current value must be collected within 90 days prior to signing the consent form or at screening.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in the Proportion of Calcified Plaque Volume from Baseline to 12 MonthsTime frame: 12 months
  2. Oct 22, 2026
    Start date Dec 31, 2026→Oct 19, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07704918
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Oct 19, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Zackry Morgan
Contact
zackry.morgan@cuanschutz.edu
720-848-5494
Caitlin Bell, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Statins · Ezetimibe · PCSK9 Inhibitor

Start the discussion